CTI-2 Inhibits Metastasis and Epithelial-Mesenchymal Transition of Breast Cancer Cells by Modulating MAPK Signaling Pathway
Abstract
:1. Introduction
2. Results
2.1. CTI-2 Affected the Migration of Breast Carcinoma Cells
2.2. CTI-2 Inhibits EMT in Breast Carcinoma Cells
2.3. RNA Sequencing Reveals That Pathways Were enriched in CTI-2 Treated Breast Carcinoma Cells
2.4. CTI-2 Blocks the MAPK Signaling Pathway in Human Breast Carcinoma Cells
2.5. CTI-2 Impeded the Metastasis of Human Breast Carcinoma Cells in vivo
3. Discussion
4. Materials and Methods
4.1. Reagents and Antibodies
4.2. Cell Line and Cell Culture
4.3. MTT Assay
4.4. Wound Healing Assay
4.5. Transwell Assay
4.6. Quantitative RT-PCR
4.7. Western Blotting
4.8. Immunofluorescence
4.9. RNA-Sequencing
4.10. In vivo Metastasis Assay
4.11. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Li, J.; Feng, W.; Lu, H.; Wei, Y.; Ma, S.; Wei, L.; Liu, Q.; Zhao, J.; Wei, Q.; Yao, J. Artemisinin inhibits breast cancer-induced osteolysis by inhibiting osteoclast formation and breast cancer cell proliferation. J. Cell. Physiol. 2019, 234, 12663–12675. [Google Scholar] [CrossRef]
- He, Z.-Y.; Wu, S.-G.; Peng, F.; Zhang, Q.; Luo, Y.; Chen, M.; Bao, Y. Up-Regulation of RFC3 Promotes Triple Negative Breast Cancer Metastasis and is Associated With Poor Prognosis Via EMT. Transl. Oncol. 2017, 10, 1–9. [Google Scholar] [CrossRef] [Green Version]
- Gu, H.-F.; Mao, X.-Y.; Du, M. Prevention of breast cancer by dietary polyphenols—role of cancer stem cells. Crit. Rev. Food Sci. Nutr. 2020, 60, 810–825. [Google Scholar] [CrossRef] [PubMed]
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ferlay, J.; Colombet, M.; Soerjomataram, I.; Parkin, D.M.; Piñeros, M.; Znaor, A.; Bray, F. Cancer statistics for the year 2020: An overview. Int. J. Cancer 2021, 149, 778–789. [Google Scholar] [CrossRef]
- Weigelt, B.; Peterse, J.L.; Van ’t Veer, L.J. Breast cancer metastasis: Markers and models. Nat. Rev. Cancer 2005, 5, 591–602. [Google Scholar] [CrossRef]
- Chaffer, C.L.; Weinberg, R.A. A Perspective on Cancer Cell Metastasis. Science 2011, 331, 1559–1564. [Google Scholar] [CrossRef]
- Song, C.; Zhou, C. HOXA10 mediates epithelial-mesenchymal transition to promote gastric cancer metastasis partly via modulation of TGFB2/Smad/METTL3 signaling axis. J. Exp. Clin. Cancer Res. 2021, 40, 62. [Google Scholar] [CrossRef]
- Hao, Y.; Xiao, Y.; Liao, X.; Tang, S.; Xie, X.; Liu, R.; Chen, Q. FGF8 induces epithelial-mesenchymal transition and promotes metastasis in oral squamous cell carcinoma. Int. J. Oral Sci. 2021, 13, 6. [Google Scholar] [CrossRef]
- Yeung, K.T.; Yang, J. Epithelial-mesenchymal transition in tumor metastasis. Mol. Oncol. 2017, 11, 28–39. [Google Scholar] [CrossRef] [Green Version]
- Lim, W.-C.; Kim, H.; Kim, Y.-J.; Jeon, B.-N.; Kang, H.-B.; Ko, H. Catechol inhibits epidermal growth factor-induced epithelial-to-mesenchymal transition and stem cell-like properties in hepatocellular carcinoma cells. Sci. Rep. 2020, 10, 7620. [Google Scholar] [CrossRef]
- Chung, H.-H.; Lee, C.-T.; Hu, J.-M.; Chou, Y.-C.; Lin, Y.-W.; Shih, Y.-L. NKX6.1 Represses Tumorigenesis, Metastasis, and Chemoresistance in Colorectal Cancer. Int. J. Mol. Sci. 2020, 21, 5106. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Devocelle, A.; Desterke, C.; de Souza, L.; Hadadi, É.; Acloque, H.; Foudi, A.; Xiang, Y.; Ballesta, A.; Chang, Y.; et al. BMAL1 Knockdown Leans Epithelial–Mesenchymal Balance toward Epithelial Properties and Decreases the Chemoresistance of Colon Carcinoma Cells. Int. J. Mol. Sci. 2021, 22, 5247. [Google Scholar] [CrossRef]
- Zhong, F.-J.; Sun, B.; Cao, M.-M.; Xu, C.; Li, Y.-M.; Yang, L.-Y. STMN2 mediates nuclear translocation of Smad2/3 and enhances TGFβ signaling by destabilizing microtubules to promote epithelial-mesenchymal transition in hepatocellular carcinoma. Cancer Lett. 2021, 506, 128–141. [Google Scholar] [CrossRef] [PubMed]
- Feng, S.; Liu, W.; Bai, X.; Pan, W.; Jia, Z.; Zhang, S.; Zhu, Y.; Tan, W. LncRNA-CTS promotes metastasis and epithelial-to-mesenchymal transition through regulating miR-505/ZEB2 axis in cervical cancer. Cancer Lett. 2019, 465, 105–117. [Google Scholar] [CrossRef]
- Li, Y.; Lin, Z.; Chen, B.; Chen, S.; Jiang, Z.; Zhou, T.; Hou, Z.; Wang, Y. Ezrin/NF-kB activation regulates epithelial- mesenchymal transition induced by EGF and promotes metastasis of colorectal cancer. Biomed. Pharmacother. 2017, 92, 140–148. [Google Scholar] [CrossRef] [PubMed]
- Tong, L.; Shen, S.; Huang, Q.; Fu, J.; Wang, T.; Pan, L.; Zhang, P.; Chen, G.; Huang, T.; Li, K.; et al. Proteasome-dependent degradation of Smad7 is critical for lung cancer metastasis. Cell Death Differ. 2019, 27, 1795–1806. [Google Scholar] [CrossRef]
- Zou, J.; Huang, R.; Li, H.; Wang, B.; Chen, Y.; Chen, S.; Ou, K.; Wang, X. Secreted TGF-beta-induced protein promotes aggressive progression in bladder cancer cells. Cancer Manag. Res. 2019, 11, 6995–7006. [Google Scholar] [CrossRef] [Green Version]
- Yu, J.; Zhou, Z.; Wei, Z.; Wu, J.; OuYang, J.; Huang, W.; He, Y.; Zhang, C. FYN promotes gastric cancer metastasis by activating STAT3-mediated epithelial-mesenchymal transition. Transl. Oncol. 2020, 13, 100841. [Google Scholar] [CrossRef] [PubMed]
- Mittal, V. Epithelial Mesenchymal Transition in Tumor Metastasis. Annu. Rev. Pathol. 2018, 13, 395–412. [Google Scholar] [CrossRef]
- Xu, G.; Zhao, H.; Xu, J.; Zhang, Y.; Qi, X.; Shi, A. Hard antler extract inhibits invasion and epithelial–mesenchymal transition of triple-negative and Her-2+ breast cancer cells by attenuating nuclear factor-κB signaling. J. Ethnopharmacol. 2020, 269, 113705. [Google Scholar] [CrossRef] [PubMed]
- Xiong, Y.; Yuan, L.; Chen, S.; Xu, H.; Peng, T.; Ju, L.; Wang, G.; Xiao, Y.; Wang, X. WFDC2 suppresses prostate cancer metastasis by modulating EGFR signaling inactivation. Cell Death Dis. 2020, 11, 537. [Google Scholar] [CrossRef] [PubMed]
- Smith, B.N.; Bhowmick, N.A. Role of EMT in Metastasis and Therapy Resistance. J. Clin. Med. 2016, 5, 17. [Google Scholar] [CrossRef] [Green Version]
- Nieto, M.A.; Huang, R.Y.-J.; Jackson, R.A.; Thiery, J.P. EMT: 2016. Cell 2016, 166, 21–45. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cordover, E.; Minden, A. Signaling pathways downstream to receptor tyrosine kinases: Targets for cancer treatment. J. Cancer Metastasis Treat. 2020, 2020. [Google Scholar] [CrossRef]
- Corso, G.; Velho, S.; Paredes, J.; Pedrazzani, C.; Martins, D.; Milanezi, F.; Pascale, V.; Vindigni, C.; Pinheiro, H.; Leite, M.; et al. Oncogenic mutations in gastric cancer with microsatellite instability. Eur. J. Cancer 2011, 47, 443–451. [Google Scholar] [CrossRef]
- Braicu, C.; Buse, M.; Busuioc, C.; Drula, R.; Gulei, D.; Raduly, L.; Rusu, A.; Irimie, A.; Atanasov, A.G.; Slaby, O.; et al. A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer. Cancers 2019, 11, 1618. [Google Scholar] [CrossRef] [Green Version]
- Whitmarsh, A.J. Regulation of gene transcription by mitogen-activated protein kinase signaling pathways. Biochim. Biophys. Acta Bioenerg. 2007, 1773, 1285–1298. [Google Scholar] [CrossRef]
- Chappell, W.H.; Steelman, L.S.; Long, J.M.; Kempf, R.C.; Abrams, S.L.; Franklin, R.A.; Bäsecke, J.; Stivala, F.; Donia, M.; Fagone, P.; et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health. Oncotarget 2011, 2, 135–164. [Google Scholar] [CrossRef] [Green Version]
- Kim, E.K.; Choi, E.-J. Compromised MAPK signaling in human diseases: An update. Arch. Toxicol. 2015, 89, 867–882. [Google Scholar] [CrossRef] [PubMed]
- Wagner, E.F.; Nebreda, Á.R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 2009, 9, 537–549. [Google Scholar] [CrossRef]
- Cargnello, M.; Roux, P.P. Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases. Microbiol. Mol. Biol. Rev. 2011, 75, 50–83. [Google Scholar] [CrossRef] [Green Version]
- Jiang, W.; Wang, X.; Zhang, C.; Xue, L.; Yang, L. Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer. Oncol. Lett. 2020, 19, 1842–1848. [Google Scholar] [CrossRef] [PubMed]
- Cotrim, C.Z.; Fabris, V.T.; Doria, M.L.; Lindberg, K.; Gustafsson, J.-Å.; Amado, F.; Lanari, C.; Helguero, L. Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells. Oncogene 2013, 32, 2390–2402. [Google Scholar] [CrossRef] [Green Version]
- Ghauri, M.A.; Su, Q.; Ullah, A.; Wang, J.; Sarwar, A.; Wu, Q.; Zhang, D.; Zhang, Y. Sanguinarine impedes metastasis and causes inversion of epithelial to mesenchymal transition in breast cancer. Phytomedicine 2021, 84, 153500. [Google Scholar] [CrossRef] [PubMed]
- Wang, T.; Seah, S.; Loh, X.; Chan, C.-W.; Hartman, M.; Goh, B.-C.; Lee, S.-C. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. Oncotarget 2015, 7, 2532–2544. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yin, L.; Duan, J.-J.; Bian, X.-W.; Yu, S.-C. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020, 22, 61. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ke, J.; Han, W.; Meng, F.; Guo, F.; Wang, Y.; Wang, L. CTI-2 Inhibits Metastasis and Epithelial-Mesenchymal Transition of Breast Cancer Cells by Modulating MAPK Signaling Pathway. Int. J. Mol. Sci. 2021, 22, 12229. https://doi.org/10.3390/ijms222212229
Ke J, Han W, Meng F, Guo F, Wang Y, Wang L. CTI-2 Inhibits Metastasis and Epithelial-Mesenchymal Transition of Breast Cancer Cells by Modulating MAPK Signaling Pathway. International Journal of Molecular Sciences. 2021; 22(22):12229. https://doi.org/10.3390/ijms222212229
Chicago/Turabian StyleKe, Junfeng, Wenzhao Han, Fanwei Meng, Feng Guo, Yuhong Wang, and Liping Wang. 2021. "CTI-2 Inhibits Metastasis and Epithelial-Mesenchymal Transition of Breast Cancer Cells by Modulating MAPK Signaling Pathway" International Journal of Molecular Sciences 22, no. 22: 12229. https://doi.org/10.3390/ijms222212229